Association of Mac‐2‐binding protein glycosylation isomer level with nutritional status in chronic liver disease

Eso, Yuji; Takai, Atsushi; Taura, Kojiro; Takahashi, Ken; Ueda, Yoshihide; Marusawa, Hiroyuki; Seno, Hiroshi

doi:10.1111/jgh.14130

Cited by 7 publications

(11 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M2BPGi is also a potential marker for predicting hepatocarcinogenesis in patients with hepatitis B treated with nucleot(s)ide analogues, and in patients with hepatitis C treated with interferon-based therapy or DAAs [18,19]. Additionally, we have previously reported that serum M2BPGi levels correlated with liver function and nutritional status markers such as serum ALB concentration, the branched-chain amino acid to tyrosine ratio, controlled the nutritional status score, and the CP score in patients with chronic liver disease [12]. Moreover, the association between M2BPGi and nutritional status was especially high in patients with HCC.…”

Section: Discussionmentioning

confidence: 99%

“…M2BPGi has been shown to be a reliable liver fibrosis marker in patients with chronic viral hepatitis and non-alcoholic fatty liver disease [9,10,11]. Moreover, we have previously reported that serum M2BPGi levels were highly correlated with liver function and nutritional status in patients with HCC [12]. Therefore, we hypothesized that M2BPGi could be a predictor of CP grade deterioration in patients who underwent TACE for HCC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma

Eso

Takai

Takahashi

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) is the recommended first-line treatment for intermediate-stage hepatocellular carcinoma (HCC). In patients who became refractory to TACE, a treatment switch to tyrosine kinase inhibitors (TKIs) needs to be considered. However, TACE could worsen liver function, thereby narrowing the time window for a switch to TKIs because TKIs are recommended for patients with Child-Pugh grade A (CP-A). We investigated the factors associated with CP grade deterioration after TACE. Among patients who underwent TACE, 125 patients with CP-A were enrolled. The cumulative CP grade deterioration rates were 20.3%, 27.1%, and 41.4% at six months, one year, and two years, respectively. Multivariate analysis revealed that factors associated with CP grade deterioration included high Mac-2 binding protein glycosylation isomer (M2BPGi) levels (>2.00 cut-off index) and beyond the up-to-seven criteria. The cumulative CP grade deterioration rates of patients with high M2BPGi and beyond the up-to-seven criteria were 50.6% and 59.2% at six months and one year, respectively, which were significantly higher than for those in any other groups. The combination of M2BPGi and up-to-seven criteria could be a surrogate marker for predicting CP grade deterioration after TACE. In patients with intermediate-stage HCC, elevated M2BPGi levels, and beyond the up-to-seven criteria, an early treatment switch to TKIs should be considered to improve their prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma

Eso

Takai

Takahashi

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ALBI score and mALBI grade were calculated as previously reported [19,26]. The CONUT score was calculated using the serum ALB, total cholesterol, and total lymphocyte count as was described previously [27,28]. The FIB-4 index was calculated by age (years) × AST (IU/L)/PLT counts (×10 9 /L) × √ ALT (IU/L) [29], while M2BPGi levels were measured using the HISCL M2BPGi kit (Sysmex, Hyogo, Japan) [30].…”

Section: Methodsmentioning

confidence: 99%

Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma

Eso

Nakano

Mishima

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intensity of lenvatinib, as it is the first oral MTA where the dose is based on the patient's weight. We aimed to evaluate the utility of 2M-DBR (the delivered dose intensity/body surface area ratio at 60 days) by comparing the relationship between 2M-DBR, 2M-RDI (RDI at 60 days), and the therapeutic response. The therapeutic response to lenvatinib was evaluated in 45 patients who underwent computed tomography 8-12 weeks after treatment initiation. We also investigated the clinical factors associated with high 2M-DBR. The area under the receiver operating characteristic of 2M-DBR that predicts the response to lenvatinib was higher than that of 2M-RDI (0.8004 vs. 0.7778). Patients with high 2M-DBR achieved significantly better objective responses and disease control rates than those with low 2M-DBR (p < 0.0001 and 0.0008). Patients with high 2M-DBR experienced significantly longer progression-free survival (PFS) than those with low 2M-DBR (p = 0.0001), while there was no significant correlation between 2M-RDI levels and PFS (p = 0.2198). Patients who achieved higher levels of 2M-DBR had a significantly better modified ALBI grade (p = 0.0437), better CONUT score (p = 0.0222), and higher BTR (p = 0.0281). Multivariate analysis revealed that high 2M-DBR was the only significant factor associated with longer PFS. In conclusion, 2M-DBR could be an important factor that reflects treatment intensity and useful for predicting the response to lenvatinib against HCC, instead of 2M-RDI.Cancers 2020, 12, 49 2 of 12 based on the two Phase III studies [4,5]. However, due to its various adverse events (AEs) and limited efficacy, identification of novel MTA compounds has been required. Recently, lenvatinib (Lenvima ® , Eisai Co., Ltd., Tokyo, Japan) was approved as a novel first-line MTA for unresectable HCC in the EU, USA, and Asia, including Japan, China, Korea, and Taiwan, based on the Phase III REFLECT trial [6].In order to optimize and maximize the therapeutic effects of pharmacotherapy, especially in the case of anticancer drug treatment, it is essential to appropriately evaluate the patient's condition before administration, sufficiently manage AEs after initiation, and keep the dose intensity (DI) high. The practicality of relative dose intensity (RDI), calculated as the percentage of the delivered DI divided by the standard DI, has been shown to be an indicator of the treatment intensity of anticancer drugs [7]. The correlations between RDI and therapeutic efficacy were reported in various types of cancers, including breast cancer [8], pancreatic ductal adenocarcinoma [9], renal cell carcinoma [10], malignant lymphoma [11], and HCC [12]. However, since lenvatinib is the first oral MTA that is dosed by the patient's weight (8 mg once...

show abstract

“…T A B L E 2Note: Data represented as mean � SD.Abbreviations: CLD, chronic liver disease; MELD, model for end-stage liver disease; M2BPDI, Mac-2 binding protein glycan isomer; PELD, pediatric endstage liver disease 21. Also significantly higher serum…”

mentioning

confidence: 99%

Mac‐2 binding protein glycan isomer as noninvasive tool to assess liver fibrosis in children with chronic liver disease

Behairy

Elgendy

Ibrahim

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

Aim: This study is aimed to measure the value of serum Mac-2 binding protein glycan isomer (M2BPGI) in children with chronic liver diseases in comparison with liver biopsy and serum biomarkers. Methods: Comparative cross-sectional study included 100 children with chronic liver diseases and 50 healthy age/sex-matched control group. All subjects were evaluated via medical history, clinical, radiological and laboratory examinations. Liver biopsy was performed for studied patients and serum M2BPGI level was measured by Enzyme Linked Immune Sorbent Assay (ELISA) in all studied subjects. Results: Serum M2BPGI level increased more significantly in chronic liver disease patients (6.04 � 2.72 ng/ml) than in healthy controls (1.12 � 0.83 ng/ml) (P < 0.001). M2BPGI level was significantly elevated with progressive fibrosis (P < 0.001), and differed significantly between high and low Child-Pugh score, pediatric end-stage liver disease score and model for end-stage liver disease score score. Serum M2BPGI was correlated with serum biomarkers and degree of fibrosis in patients. Conclusion: M2BPGI could be used as one of noninvasive tools for detecting and staging of hepatic fibrosis in Egyptian children with chronic liver disease.

show abstract

Association of Mac‐2‐binding protein glycosylation isomer level with nutritional status in chronic liver disease

Abstract: Serum M2BPGi levels are correlated with nutritional status markers in patients with CLD and could be a useful clinical marker of malnutrition.

Cited by 7 publications

References 52 publications

Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma

Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma

Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma

Mac‐2 binding protein glycan isomer as noninvasive tool to assess liver fibrosis in children with chronic liver disease

Contact Info

Product

Resources

About